Antimicrobial resistance in Democratic Republic of Congo: the way forward
Aymar Akilimali(Roslin Institute), Olivier Nyakio(Faculty (United Kingdom)), Chris Kitumaini(Université libre des Pays des Grands Lacs), Michel K. Mirindi, Fabrice Kibukila(Université Officielle de Bukavu), Hugues Cakwira(Green Circle), Wireko Andrew Awuah(Continental (Germany)), Malik Olatunde Oduoye(Ahmadu Bello University), Gaston Masimango(Green Circle), Toussaint Amani(Université libre des Pays des Grands Lacs), Binish Javed(Atal Bihari Vajpayee Institute of Medical Sciences and Dr. Ram Manohar Lohia Hospital), Heritier Machara(Université Catholique de Bukavu), Hardy Elembwe(University of Goma)
Cited by 7
Related Papers
Revolutionary breakthrough: FDA approves CASGEVY, the first CRISPR/Cas9 gene therapy for sickle cell disease
|Annals of Medicine and Surgery|2024|87
Impacts of the advancement in artificial intelligence on laboratory medicine in low‐ and middle‐income countries: Challenges and recommendations—A literature review
|Health Science Reports|2024|62
Revolutionary breakthrough: FDA approves Vyjuvek, the first topical gene therapy for dystrophic epidermolysis bullosa
|Annals of Medicine and Surgery|2023|30
Self-medication and Anti-malarial Drug Resistance in the Democratic Republic of the Congo (DRC): A silent threat
|Tropical Medicine and Health|2022|29